// App-Quantinova.ai

P-99 : Pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract cancer: phase 3 KEYNOTE-966 trial in progress

Researchers

Presenter

  • A. Vogel

Principal Investigators

  • R. Finn

  • R. Kelley

  • J. Furuse

  • J. Edeline

  • Z. Ren

  • S. Su

  • U. Malhotra

  • A. Siegel

  • J. Valle

Medical Centers

  • Hannover Medical School, Hannover, Germany

  • Rheumatology, David Geffen School of Medicine, Los Angeles, United States

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Tokyo University Hospital, Tokyo, Japan

  • Centre Eugene-Marquis, Rennes, France

  • Huashan Hospital, Fudan University, Shanghai, China

  • Merck & Co., Inc., Kenilworth, NJ, United States,

  • University of Manchester and The Christie NHS FT, Manchester, United Kingdom

Locations

  • Germany

  • United States

  • Japan

  • France

  • China

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

  • Hepatitis C

  • Human immunodeficiency virus infection

  • Pulmonary alveolar proteinosis

  • Solid malignancies

Biomarkers

  • Programmed cell death 1 ligand 2

  • Programmed death-ligand 1

  • Cytotoxic T-lymphocyte-associated protein 4

Drug/Treatment

  • Pembrolizumab

  • Gemcitabine

  • Cisplatin

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved